A clinic study on PA-MSHA vaccine adjuvant therapy for lung cancer

JIA Qin,SUN Yi-ping,CAI Rong,WANG Chun-yan,YU Jing
DOI: https://doi.org/10.3969/j.issn.1006-5725.2007.16.013
2007-01-01
Abstract:Objective To evaluate the effectiveness and safety of pseudomonas aeruginous MSHA(PA-MSHA)vaccine used as an immune modulator.Methods We conducted a non-blinded,randomized,controlled trial.40 patients with lung cancer were randomly assigned to receive either chemotherapy alone(control group,n = 20)or the same therapy plus PA-MSHA vaccine(experimental group,n = 20).Immune function was measured before and after treatment.The response rate and the infection rate were evaluated following completion of the therapy.Results The response rate(CR + PR)was 65% in the experimental group and 45% in the control group(P < 0.01).The infection rate was 15% in the experimental group and 40% in the control group(P < 0.05).After treatment,C3,C4,the ratio of CD4 to CD8,NK cell activity,and IL-2 level in the experimental group were significantly higher than those in the control group(P < 0.05).Some adverse events occurred in 3 patients on PA-MSHA vaccine but relieved spontaneously.Conclusion PA-MSHA vaccine can evidently enhance the immune function of patients with lung cancer,protect them against infection,and improve the efficacy of chemotherapy.
What problem does this paper attempt to address?